/ Home / News / Company News /

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA

Release Time: 2020-09-11

News Source: SenovaTech

Author: Operation Dept.

Product information:

Product name:Empagliflozin       Cas No.:864070-44-0

Molecular Formula:C23H27ClO7      Molecular Weight:450.90928

Structure:

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图1)

Key intermediates information:

Product name:(3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane       

Cas No.:915095-89-5

Molecular Formula:C17H16BrClO2      Molecular Weight:367.66500

Structure:

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图2)

Product name:(1S)-1,5-anhydro-2,3,4,6-tetra-O-acteyl-1-C-[4-chloro-3-[[4-[[(3S)

-tetrahydrofu-ran-3-yl]oxy]phenyl] methyl]phenyl]-D-Glucitol      

Cas No.:915095-99-7

Molecular Formula:C31H35ClO11      Molecular Weight:619.056

Structure:

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图3)

..............................................................................................................................


Empagliflozin, sold under the brand name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes.


Empagliflozin is used in combination with proper diet and exercise to help people with type 2 diabetes lower their blood sugar levels. It can be used alongside other medications for type 2 diabetes such as metformin, sulfonylureas, and insulin. When compared to a placebo, empagliflozin led to a drop of 0.7% in hemoglobin A1c, a long-term marker of blood glucose levels.


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图4)

............................................................................................................


The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014.SENOVE started to study Empagliflozin API in 2015, and it only took two years from small trial to medium trial to commercialization.The capacity of EMPAGLIFLOZIN API is 1500kg/month with Facility GMP and DMF.The capacity of the key intermediates(N-1&N-2) are 1000-3000kg/month now.


Headquarter Office in ShenZhen, R&D center in HangZhou, GMP factory in JiangSu.

(Please note:All products which might have patent infringment are used for R&D only/ It's Not Senova's responsibility in those markets where there are patent infringement regulated.)


PLANT:

EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图5)


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图6)


WORKSHOP


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图7)


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图8)


R&D ROOM:


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图9)


WAREHOUSE:


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图10)


PACKING: 


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图11)


COA:


EMPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA(图12)


.................................................................................................................................

SENOVA:

Senova means“Step For Innovation", we are a professional company who's supplying APIs(mainly New Generics), Advanced Intermediates and KSM(Key Starting Materials) as well as technical Support/Registration support/Custom synthesis service in pharmaceutical and related field , we focus on serving those manufacturers' New Generics Projects from R&D stage to Commercial Stage from meterials to documents support(DMF/CMC). For those regulated markets, we secure all of our products can be produced under GMP regulation with Full Documentation.